IAC/Interactivecorp vs uniQure N.V. Ordinary Shares — how do they compare? IAC/Interactivecorp trades at $40.57 (market cap $3.04B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: IAC/Interactivecorp is far larger — about 2.1× uniQure N.V. Ordinary Shares's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 80 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| PPLI | QURE | |
|---|---|---|
Market Cap | $3.04B | $1.48B |
Volume | 686,384 | 2,488,780 |
Sector | Media | Health |
52-Week High | $47.62 | $70.59 |
52-Week Low | $31.52 | $9.03 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $3.52B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.56, down 0.73% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a net loss of $104.03M in 2025 despite strong gross margins of 66.35%, with valuation metrics appearing attractive at P/E of 6.91 and P/B of 0.6. Recent MGM acquisition speculation has driven significant volatility, with shares surging 11.3% on takeover rumors according to Zacks Investment Research on September 28, 2026.
The outlook remains speculative with 71% analyst buy ratings supporting potential upside from strategic developments, though fundamental weakness in recent earnings and negative cash flow trends present significant risks. Investors face binary outcomes dependent on MGM deal progression versus underlying business challenges in the media sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →